A Phase 3 Open-label Study of Infacort in Neonates, Infants and Children Less Than 6 Years of Age With Adrenal Insufficiency

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 21 Jul 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

16 Nov 2021 According to an EffRx media release, the company received swiss marketing authorization for Alkindi for the treatment of paediatric adrenocortical insufficiency (AI), based on data from this trial.
15 May 2018 Primary endpoint has been met. (Serum Cortisol Concentration up to 240 Minutes), according to a Diurnal media release
15 May 2018 According to a Diurnal media release, Dr Oliver Blankenstein is co-investigator in his trial.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com